Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate.
We report a case of invasive trichosporonosis due to Trichosporon beigelii originating in the left wrist of a bone marrow transplant recipient who was receiving caspofungin acetate as prophylaxis against invasive Aspergillus infection. While the patient's neutrophil count was recovering, treatment with fluconazole and amphotericin B lipid complex resulted in a complete clinical response.
Goodman
Daniel
D
Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA. goodmand@mskcc.org
Pamer
Eric
E
Jakubowski
Ann
A
Morris
Carol
C
Sepkowitz
Kent
K
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000517:prevention & control; D016026:Bone Marrow Transplantation; D000077336:Caspofungin; D018890:Chemoprevention; D004359:Drug Therapy, Combination; D054714:Echinocandins; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D055666:Lipopeptides; D008297:Male; D009181:Mycoses / Q000188:drug therapy*; D009894:Opportunistic Infections / Q000188:drug therapy; D010455:Peptides; D010456:Peptides, Cyclic; D014250:Trichosporon / Q000187:drug effects
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D000666:Amphotericin B; D015725:Fluconazole; D000077336:Caspofungin